Ixekizumab for treating ankylosing spondylitis

Sonam Kiwalkar, Secia Beier, Atul Deodhar

Research output: Contribution to journalReview article

Abstract

Axial spondyloarthritis (axSpA) is an umbrella term that includes ankylosing spondylitis and nonradiographic axSpA. Presence or absence of definitive sacroiliitis on radiographs differentiates ankylosing spondylitis (also called radiographic axSpA) from nonradiographic axSpA. There is growing evidence that indicates IL-17 pathway is a key contributor to the pathogenesis of axSpA. Ixekizumab (IXE) is an IL-17A inhibitor (IL-17i) with data to support its use in patients with radiographic axSpA. The pharmacologic properties of IXE were reviewed. Data regarding the use and efficacy of IXE in patients with radiographic axSpA were evaluated. Quality life outcomes and safety profiles of IXE were examined as well. By comparison with other chronic inflammatory arthritides, the number of targeted treatment options for axSpA is currently limited to tumor necrosis factor inhibitor (TNFi) and IL-17i secukinumab. IXE has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes, with an acceptable safety profile in patients with radiographic axSpA. The current results discussed in this article support use of IXE as a treatment option for TNFi naive as well as in subjects with prior inadequate response to or intolerance to TNFi agents.

Original languageEnglish (US)
Pages (from-to)1273-1282
Number of pages10
JournalImmunotherapy
Volume11
Issue number15
DOIs
StatePublished - Jan 1 2019

Fingerprint

LY2439821
Ankylosing Spondylitis
Interleukin-17
Tumor Necrosis Factor-alpha
Sacroiliitis
Safety
Arthritis
Quality of Life

Keywords

  • ankylosing spondylitis
  • IL-17 inhibitor
  • ixekizumab
  • nonradiographic axial spondyloarthritis
  • radiographic axial spondyloarthritis
  • spondyloarthritis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Ixekizumab for treating ankylosing spondylitis. / Kiwalkar, Sonam; Beier, Secia; Deodhar, Atul.

In: Immunotherapy, Vol. 11, No. 15, 01.01.2019, p. 1273-1282.

Research output: Contribution to journalReview article

Kiwalkar, Sonam ; Beier, Secia ; Deodhar, Atul. / Ixekizumab for treating ankylosing spondylitis. In: Immunotherapy. 2019 ; Vol. 11, No. 15. pp. 1273-1282.
@article{c1f4e8848f0344249dac9396ff7dcfb9,
title = "Ixekizumab for treating ankylosing spondylitis",
abstract = "Axial spondyloarthritis (axSpA) is an umbrella term that includes ankylosing spondylitis and nonradiographic axSpA. Presence or absence of definitive sacroiliitis on radiographs differentiates ankylosing spondylitis (also called radiographic axSpA) from nonradiographic axSpA. There is growing evidence that indicates IL-17 pathway is a key contributor to the pathogenesis of axSpA. Ixekizumab (IXE) is an IL-17A inhibitor (IL-17i) with data to support its use in patients with radiographic axSpA. The pharmacologic properties of IXE were reviewed. Data regarding the use and efficacy of IXE in patients with radiographic axSpA were evaluated. Quality life outcomes and safety profiles of IXE were examined as well. By comparison with other chronic inflammatory arthritides, the number of targeted treatment options for axSpA is currently limited to tumor necrosis factor inhibitor (TNFi) and IL-17i secukinumab. IXE has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes, with an acceptable safety profile in patients with radiographic axSpA. The current results discussed in this article support use of IXE as a treatment option for TNFi naive as well as in subjects with prior inadequate response to or intolerance to TNFi agents.",
keywords = "ankylosing spondylitis, IL-17 inhibitor, ixekizumab, nonradiographic axial spondyloarthritis, radiographic axial spondyloarthritis, spondyloarthritis",
author = "Sonam Kiwalkar and Secia Beier and Atul Deodhar",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/imt-2019-0094",
language = "English (US)",
volume = "11",
pages = "1273--1282",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "15",

}

TY - JOUR

T1 - Ixekizumab for treating ankylosing spondylitis

AU - Kiwalkar, Sonam

AU - Beier, Secia

AU - Deodhar, Atul

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Axial spondyloarthritis (axSpA) is an umbrella term that includes ankylosing spondylitis and nonradiographic axSpA. Presence or absence of definitive sacroiliitis on radiographs differentiates ankylosing spondylitis (also called radiographic axSpA) from nonradiographic axSpA. There is growing evidence that indicates IL-17 pathway is a key contributor to the pathogenesis of axSpA. Ixekizumab (IXE) is an IL-17A inhibitor (IL-17i) with data to support its use in patients with radiographic axSpA. The pharmacologic properties of IXE were reviewed. Data regarding the use and efficacy of IXE in patients with radiographic axSpA were evaluated. Quality life outcomes and safety profiles of IXE were examined as well. By comparison with other chronic inflammatory arthritides, the number of targeted treatment options for axSpA is currently limited to tumor necrosis factor inhibitor (TNFi) and IL-17i secukinumab. IXE has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes, with an acceptable safety profile in patients with radiographic axSpA. The current results discussed in this article support use of IXE as a treatment option for TNFi naive as well as in subjects with prior inadequate response to or intolerance to TNFi agents.

AB - Axial spondyloarthritis (axSpA) is an umbrella term that includes ankylosing spondylitis and nonradiographic axSpA. Presence or absence of definitive sacroiliitis on radiographs differentiates ankylosing spondylitis (also called radiographic axSpA) from nonradiographic axSpA. There is growing evidence that indicates IL-17 pathway is a key contributor to the pathogenesis of axSpA. Ixekizumab (IXE) is an IL-17A inhibitor (IL-17i) with data to support its use in patients with radiographic axSpA. The pharmacologic properties of IXE were reviewed. Data regarding the use and efficacy of IXE in patients with radiographic axSpA were evaluated. Quality life outcomes and safety profiles of IXE were examined as well. By comparison with other chronic inflammatory arthritides, the number of targeted treatment options for axSpA is currently limited to tumor necrosis factor inhibitor (TNFi) and IL-17i secukinumab. IXE has good evidence of improved outcomes in terms of clinical efficacy, patient reported outcomes and imaging outcomes, with an acceptable safety profile in patients with radiographic axSpA. The current results discussed in this article support use of IXE as a treatment option for TNFi naive as well as in subjects with prior inadequate response to or intolerance to TNFi agents.

KW - ankylosing spondylitis

KW - IL-17 inhibitor

KW - ixekizumab

KW - nonradiographic axial spondyloarthritis

KW - radiographic axial spondyloarthritis

KW - spondyloarthritis

UR - http://www.scopus.com/inward/record.url?scp=85073490537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073490537&partnerID=8YFLogxK

U2 - 10.2217/imt-2019-0094

DO - 10.2217/imt-2019-0094

M3 - Review article

C2 - 31530049

AN - SCOPUS:85073490537

VL - 11

SP - 1273

EP - 1282

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 15

ER -